吉非贝齐 CAS#: 25812-30-0; ChemWhat 代号：137366
鉴定
| 产品名称 | 吉非罗齐 |
| IUPAC名称 | 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid |
| 分子结构 |  |
| CAS注册号 | 25812-30-0 |
| EINECS号码 | 247-280-2 |
| MDL号码 | MFCD00079335 |
| 同义词 | 吉非贝齐 25812-30-0 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid 洛皮德 耶兹勒 Decrelip Lipur CI-719 Cholespid Fibratol Fibrocit Gemfibril Gemfibromax Gemlipid Hipolixan Gemfibrozilo Gemfibrozilum Renabrazin Clearol Elmogan Fetinor Gemnpid 英诺金 Ipolipid Lanaterom Lifibron Lipigem Lipizyl Micolip Normolip Progemzal Reducel Regulip Sinelip Synbrozil Taborcil Tentroc Brozil Gozid Hidil Lipira Gemd Gevilon Uno WL-Gemfibrozil Gen-Fibro Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- Low-Lip Gem-S Lipozid 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure Gemfibrozilum [INN-Latin] Gemfibrozilo [INN-Spanish] CCRIS 318 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure EINECS 247-280-2 NSC-757024 伯尔尼 1881200 吉非罗齐（Lopid） Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)- Bolutol 切比：5296 Apo-Gemfibrozil DTXSID0020652 UNII-Q8X02027X3 汇丰7735 Gemfibrozil (Standard) Gemfibrosil Lipazil Litarek MFCD00079335 Trialmin Ausgem Pilder 化学457 Q8X02027X3 DTXCID20652 MLS000028421 Gemfibrozil [USAN:USP:INN:BAN] 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid NSC 757024 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid NCGC00016794-09 SMR000058393 Genlip CAS-25812-30-0 GEMFIBROZIL (IARC) GEMFIBROZIL [IARC] Gemfibrozilum (INN-Latin) Gemfibrozilo (INN-Spanish) GEMFIBROZIL (MART.) GEMFIBROZIL [MART.] GEMFIBROZIL (USP-RS) GEMFIBROZIL [USP-RS] 2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID GEMFIBROZIL (EP MONOGRAPH) GEMFIBROZIL [EP MONOGRAPH] Innogem Gemcor GEMFIBROZIL (USP MONOGRAPH) GEMFIBROZIL [USP MONOGRAPH] Gemfibrozil (USAN:USP:INN:BAN) CI 719 Lopid (TN) TEVA-A SR-01000000056的 Gemfibrozil (JAN/USP/INN) Gemfibrozil,(S) 4TX 普雷斯蒂克_637 dimethylpentanoic acid 频谱_000825 持续专业发展000058393 GEMFIBROZIL [MI] 114413-98-8 歌剧_ID_1658 普雷斯蒂克0_000214 普雷斯蒂克1_000214 普雷斯蒂克2_000214 普雷斯蒂克3_000214 频谱2_001097 频谱3_000440 频谱4_000562 频谱5_000750 频谱5_001991 GEMFIBROZIL [INN] GEMFIBROZIL [JAN] GEMFIBROZIL [HSDB] GEMFIBROZIL [INCI] GEMFIBROZIL [USAN] GEMFIBROZIL [VANDF] 附表4813 BSPBio_000227 BSPBio_002060 GEMFIBROZIL [WHO-DD] KBioGR_000964 KBioSS_001305 MLS001055364 MLS006011850 DivK1c_000138 频谱1500313 SPBio_001174 SPBio_002148 BPBio1_000251 GTPL3439 YSSJ5501 Gemfibrozil, analytical standard 氯719 HMS500G20 HY-B0258R KBio1_000138 KBio2_001305 KBio2_003873 KBio2_006441 KBio3_001280 C10AB04 GEMFIBROZIL [ORANGE BOOK] Gemfibrozil for system suitability NINDS_000138 HMS1568L09 HMS1920B07 HMS2090K14 HMS2091H11 HMS2095L09 HMS2230H24 HMS3259M12 HMS3655C06 HMS3712L09 Pharmakon1600-10500313 5-(2,5-dimethylphenoxy)-2,2- BCP08437 HY-B0258 Tox21_110613 Tox21_201997 Tox21_302784 BBL010807 BDBM50110590 CCG-40111 DL-414 NSC757024 s1729 STK618740 AKOS001606691 Tox21_110613_1 AB03034 AC-4225 DB01241 KS-5192 MCULE-4563546953 NC00565 IDI1_000138 NCGC00016794-01 NCGC00016794-02 NCGC00016794-03 NCGC00016794-04 NCGC00016794-05 NCGC00016794-06 NCGC00016794-07 NCGC00016794-08 NCGC00016794-10 NCGC00016794-11 NCGC00016794-13 NCGC00016794-14 NCGC00022722-03 NCGC00022722-04 NCGC00022722-05 NCGC00022722-06 NCGC00022722-07 NCGC00256601-01 NCGC00259546-01 SY052512 Gemfibrozil 100 microg/mL in Acetonitrile SBI-0051391.P003 2,2-Dimethyl-5-(2,5-zlyloxy)valeric acid AB00052003 CS-0694895的 G0368 NS00010281 SW196802-3 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaure EN300-97098 C07020 D00334 D83091 AB00052003-15 AB00052003-16 AB00052003_17 AB00052003_18 A818037 Q384295 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaure 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeric Acid 5-(2,5-dimethyphenoxy)-2,2-dimethylpentanoic acid SR-01000000056，3 SR-01000000056，4 SR-01000000056，6 SR-01000000056，7 W-107216 2,2-Dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid BRD-K11129031-001-05-1 Z1259021151 Gemfibrozil, British Pharmacopoeia (BP) Reference Standard Gemfibrozil, European Pharmacopoeia (EP) Reference Standard Gemfibrozil, United States Pharmacopeia (USP) Reference Standard Gemfibrozil, Pharmaceutical Secondary Standard; Certified Reference Material Gemfibrozil for system suitability, European Pharmacopoeia (EP) Reference Standard 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid, 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic aci |
| 分子式 | C15H22O3 |
| 分子量 | 250.33 |
| INCHI | InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17) |
| InChI键 | HEMJJKBWTPKOJG-UHFFFAOYSA-N |
| 异构体 SMILES | CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O |
物理数据
| 外观 | 白色结晶性粉末 |
| 熔点，°C |
| 334 |
| 61.2 |
| 59 - 61 |
| 58 - 70 |
| 61 - 63 |
| 沸点，°C |
| 158 - 159 |
| 密度，g·cm-3 |
| 1.09 |
| 说明（协会（MCS）） | 溶剂（协会（MCS）） | 合作伙伴（协会（MCS）） |
| 具有...的复合物的稳定常数 | 各种溶剂 | 人血清白蛋白 |
| 具有...的复合物的稳定常数 | 各种溶剂 | immobilized phospholipid membrane |
| 复合物的进一步物理性质 | H2O | LixAl2(OH)6*yH2O |
光谱
| 描述（核磁共振光谱学） | 核（核磁共振光谱学） | 溶剂（核磁共振波谱法） | 频率（NMR光谱），MHz |
| 化学位移，谱 | 13C | 氯仿 - d1 | |
| 化学位移，谱 | 1H | 氯仿 - d1 | 500 |
| 化学位移，谱 | 13C | 氯仿 - d1 | 126 |
| 光谱 | 1H | ||
| 化学位移，谱 | 1H | 氯仿 - d1 | 400 |
| 说明（红外光谱） | 溶剂（红外光谱） |
| 乐队，频谱 | |
| 光谱 | |
| 乐队 | 溴化钾 |
| 乐队 | |
| 乐队，频谱 | 溴化钾 |
| 描述（UV / VIS光谱） | 溶剂（UV / VIS光谱） | 评论（UV / VIS光谱学） | 吸收最大值（UV / VIS），nm |
| 光谱 | 198.3，275.2 | ||
| 光谱 | water, dimethyl sulfoxide | 274 | |
| 光谱 | 甲醇，水 | ||
合成路线（ROS）
| 医美问题 | 产量 |
| With dmap; dicyclohexyl-carbodiimide In dichloromethane | 98% |
| With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In tetrahydrofuran at 20℃; Inert atmosphere; | 98% |
| With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; | 94% |
安全与危害
| 象形图 |    |
| 信号 | 警告 |
| GHS危害声明 | H302（100％）：吞咽有害[警告急性毒性，口服] H351（24.62％）：怀疑引起癌症[警告致癌性] H361（26.15％）：怀疑生育能力受损或未出生的孩子[警告生殖毒性] H411（24.62％）：对水生生物有毒并具有长期持续影响[对水生环境有害，有长期危害] |
| 防范说明代码 | P203、P264、P270、P273、P280、P301+P317、P318、P330、P391、P405 和 P501 （每个P代码的对应语句可以在 GHS分类 页。） |
其他数据
| 交通 | 在室温和远离光线下 |
| HS编码 | |
| 存储 | 在室温和远离光线下 |
| 保质期 | 3 年 |
| 市场价格 |
| 药物相似性 | |
| Lipinski规则组件 | |
| 分子量 | 250.338 |
| 日志 | 3.35 |
| HBA | 2 |
| HBD | 1 |
| 匹配Lipinski规则 | 4 |
| Veber规则组件 | |
| 极性表面积（PSA） | 46.53 |
| 可旋转债券（RotB） | 6 |
| 匹配Veber规则 | 2 |
| 使用模式 |
| Gemfibrozil, with the chemical name 2,2-dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid. Gemfibrozil is a fibrate class lipid-regulating medication derived from clofibrate. It was introduced to the market in the United States in 1982. Gemfibrozil overcomes the serious hepatic toxicity associated with earlier lipid-lowering drugs such as clofibrate while retaining its efficacy. It promotes the breakdown of peripheral fat, reduces the hepatic uptake of free fatty acids, thereby decreasing intrahepatic triglyceride formation. Additionally, it inhibits the synthesis of very-low-density lipoprotein (VLDL) and reduces the generation of VLDL. |
购买试剂 | |
| 没有试剂供应商？ | 发送快速查询至 ChemWhat |
| 想要在这里被列为试剂供应商吗？ （收费服务） | 点击这里联系 ChemWhat |
批准的制造商 | |
| Caming Pharmaceutical Limited | http://www.caming.com/ |
| 想要被列为经批准的制造商（需要批准）吗？ | 请下载并填写 这种形式 并发送回 [电子邮件保护] |
联系我们以获得其他帮助 | |
| 联系我们获取其他信息或服务 | 点击这里联系 ChemWhat |